BL
TAK icon

Balentine LLC’s Takeda Pharmaceutical TAK Stock Holding History

Balentine LLC’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,182
Closed -$39K – 761
2020
Q2 		$39K Buy
+2,182
New +$39.2K ﹤0.01% 278
2019
Q4 		– Sell
-890
Closed -$15K – 745
2019
Q3 		$15K Sell
890
-176
-17% -$3.04K ﹤0.01% 278
2019
Q2 		$19K Buy
1,066
+215
+25% +$3.91K ﹤0.01% 219
2019
Q1 		$17K Buy
+851
New +$17.1K ﹤0.01% 220

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balentine LLC's TAK Position: Q3 2020 in Review

Balentine LLC sold out of Takeda Pharmaceutical (TAK) in Q3 2020, closing a stake of 2,182 shares — an estimated $39K sold.

Balentine LLC first reported a position in TAK in Q1 2019 and held it in 4 quarters. The position peaked at $39K in Q2 2020. 310 funds tracked by Wall St. Rank hold TAK as of Q3 2020.

  • Balentine LLC reported no remaining Takeda Pharmaceutical position as of Q3 2020 after selling out during the quarter.
  • Balentine LLC sold 2,182 Takeda Pharmaceutical shares in Q3 2020, an estimated $39K.
  • Balentine LLC first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 4 quarters.
  • Balentine LLC's Takeda Pharmaceutical position peaked at $39K in Q2 2020.
  • 310 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.